laboratorios-clinicos.mdbanalisis-clinicos-catbioanalisis-clinicos-abolab

There are an estimated 333 million cases of sexually transmitted infections (STIs) in adults aged 15-49, of which 16 million are in Europe.

It is estimated that, worldwide, there are 270 million cases of infections caused by HUMAN PAPILOMA VIRUS (HPV). Of these, 27 million have genital warts, another 27 million low-grade lesions, 1.5 million high-grade lesions and 0.4 million cervical carcinomas.

HUMAN PAPILOMAVIRUS (HPV) are double-stranded DNA viruses with a genome of approximately 8,000 base pairs.

Based on their association with cervical cancer and precursor lesions, Human Papillomavirus can be grouped into high and low risk types:
Low risk subjects include types 6, 11, 26, 40, 42, 53, 54, 55, 61, 62, 64, 67, 70, 71, 72, 73, 81, 82, 83, IS39 and CP6108.
◦ High-risk HPVs include types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.

Within the group of Human Papillomavirus of low risk are the types 6 and 11 associated with condyloma acuminata. Among those at high risk, the types 16 and 18, associated with cervical carcinoma, stand out. Within this group, type 16 is probably the one that occurs most frequently and is associated with squamous cell cancer, followed by type 18, preferentially associated with adenocarcinoma.

Sexually acquired HPV can produce several types of lesions depending on the type of Human Papillomavirus involved:

The lesions associated with types 6 and 11 can range from latent infections without clinical expression, to subclinical infections, to anogenital warts that do not evolve into neoplasms. In contrast, high-risk HPV types (mainly types 16 and 18) are the cause of long-acting active infections, with change in infected cells, and lead to genital neoplasias

Note that our Cytogenetics / Molecular Biology Section has specialists with proven experience who will always inform and provide all support for the interpretation of the results obtained. The sample is very simple to take and during this summer we have a special rate for this test.

Detailed information of the method used in the analysis

Linear Array Genotyping Test HPV Genotyping Test

The HPV genotyping test (human papillomavirus) LINEAR ARRAY is a qualitative in vitro test for the detection of human papillomavirus in clinical samples. The assay uses target DNA amplification using polymerase chain reaction (PCR) and nucleic acid hybridization and detects thirty-seven genotypes of anogenital HPV DNA in cervical cells obtained and preserved with PreservCyt®.

The Procedure Consists of:

  1. Preparation of the sample.
  2. Amplification of DNA using HPV primers.
  3. Hybridization of the amplified product with oligonucleotide probes.
  4. Detection of the union of the amplified product by colorimetric determination.

>> Test data sheet: Detection and genotyping Human Papillomavirus (HPV) (VPAE)

Advantages of the Technique

Its ability to detect a broad spectrum of genotypes safely and sensibly using the Linear Array Test of Genotyping HPV Genotyping Test:

  • Improved accuracy in the determination of high and low risk viruses.
  • Better understanding of the role of persistent HPV infection in the natural history of cervical cancer.

It is fully demonstrated that this technique improves the determination of high-risk viruses and avoids false negatives.

With the Linear Array Test of Genotyping HPV the sensitivity of type-specific amplification has increased substantially, especially in those samples infected with multiple HPV types.

Linear Array Genotyping Test HPV allows sensitive amplification and accurate determination of a broad spectrum of HPV genotypes.

Amplification and detection with Linear Array Test of Genotyping HPV is compatible with automation, facilitating the use of this method in extensive screening studies.

Technical Qualities

  • Sensitive and non-invasive determination.
  • No cross-reactivity with viruses, bacteria, protozoa and fungi that can be found in cervical samples.
  • The sensitivity and specificity of the test in the determination of high-risk virus were 96% and 99%, respectively.
  • In-laboratory reproducibility, up to 99%.
  • Excellent interlaboratory reproducibility> 95%.
  • Precision of 95-100%.
  • High reliability.
  • The accuracy of the assay was excellent.

Linear Array Genotyping Test HPV Genotyping Test

The HPV genotyping test (human papillomavirus) LINEAR ARRAY is a qualitative in vitro test for the detection of human papillomavirus in clinical samples. The assay uses target DNA amplification using polymerase chain reaction (PCR) and nucleic acid hybridization and detects thirty-seven genotypes of anogenital HPV DNA in cervical cells obtained and preserved with PreservCyt®.

The Procedure Consists of:

  1. Preparation of the sample.
  2. Amplification of DNA using HPV primers.
  3. Hybridization of the amplified product with oligonucleotide probes.
  4. Detection of the union of the amplified product by colorimetric determination.

>> Test data sheet: Detection and genotyping Human Papillomavirus (HPV) (VPAE)

Its ability to detect a broad spectrum of genotypes safely and sensibly using the Linear Array Test of Genotyping HPV Genotyping Test:

  • Improved accuracy in the determination of high and low risk viruses.
  • Better understanding of the role of persistent HPV infection in the natural history of cervical cancer.

It is fully demonstrated that this technique improves the determination of high-risk viruses and avoids false negatives.

With the Linear Array Test of Genotyping HPV the sensitivity of type-specific amplification has increased substantially, especially in those samples infected with multiple HPV types.

Linear Array Genotyping Test HPV allows sensitive amplification and accurate determination of a broad spectrum of HPV genotypes.

Amplification and detection with Linear Array Test of Genotyping HPV is compatible with automation, facilitating the use of this method in extensive screening studies.

  • Sensitive and non-invasive determination.
  • No cross-reactivity with viruses, bacteria, protozoa and fungi that can be found in cervical samples.
  • The sensitivity and specificity of the test in the determination of high-risk virus were 96% and 99%, respectively.
  • In-laboratory reproducibility, up to 99%.
  • Excellent interlaboratory reproducibility> 95%.
  • Precision of 95-100%.
  • High reliability.
  • The accuracy of the assay was excellent.

If the analysis is carried out in the central laboratory of Barcelona or in the central laboratory of Madrid, it will be able to have the results urgently and receive preferential treatment in the possible. Visit our centers to see which is your nearest extraction center.

PRICE: 120€ 110€

Method: P.C.R

Type of sample: Vaginal, Urethral, EndocervicalFroth

Response time: 21 days

Complete Drug Pack

Results in 4 days.

85,06€ 70€

Pack STD (Blood + Frotis)

Results in 4 days.

129€